^
Association details:
| Biomarker: | KRAS G12R |
|---|---|
| Cancer: | Pancreatic Adenocarcinoma |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS G12R-mutant pancreatic ductal adenocarcinoma
Published date:
01/06/2021
Excerpt:
Results From August 2017 to February 2018 a total of 8 patients with confirmed somatic KRASG12R mutations and a median age of 61.5 years were treated with selumetinib...After a median follow-up period of 8.5 months (range 2 to 20), three patients had stable disease for more than 6 months while receiving selumetinib. No patients achieved an objective partial response. Median progression-free survival (PFS) was 3.0 months (95% CI, 0.8-8.2) and median overall survival (OS) 9 months (95% CI, 2.5-20.9).
DOI:
10.1007/s10637-020-01044-8
Trial ID:
